🔥Telegram İfşa

We added a Waters Corporation Xevo G3 to our #bioanalytical lineup, the 1st to be installed in the region. It will be used for our #metabolite ID studies, including incubations with BioIVT #HepatoPac #hepatocyte-fibroblast co-cultures for low turnover compounds: bioivt.com/in-vitro-metab…

We asked some of our #druginteractions experts to address frequently asked questions about enzyme induction studies and elaborate on recommendations to achieve successful regulatory submission. Take a look at their responses here: bioivt.com/blogs/in-vitro…

Our most popular #ADME blog entry for 2022 was our infographic about how you can leverage your data to showcase your compound in ways that will maximize its value. Take a look! bioivt.com/resources/arti…

How does #drugmetabolism & #pharmacokinetics fit into #drugdevelopment? Read an overview of #DMPK & derisking strategies associated with using #preclinical #invitro data to evaluate metabolite formation & risk of potential #druginteractions: bioivt.com/blogs/what-is-…

Our next newsletter with links to recordings from our June Symposium, info on our new #invitro #ADME & #druginteractions study tiers, and more is scheduled for early July. Make sure you’ve subscribed to receive emails from BioIVT in order to receive it! hubs.ly/Q01SQsX-0

The countdown until the end of use for XenoTech’s current social media accounts has begun. We’ll be making the switch on July 15th, so make sure you’ve followed BioIVT by then to ensure you don’t miss any important #ADME, #DMPK or #DrugInteraction research news!

Since many compounds bind to red blood cells, the majority of polled researchers said they regularly conduct red blood cell partitioning with plasma protein binding studies to determine #pharmacokinetic parameters: bioivt.com/blogs/why-do-m…

Take a look at our industry survey results to see when most researchers are performing #ADME/#DMPK & #DrugInteractions testing, what the top 4 repercussions & risks are from postponing, & top 3 benefits to running more testing during #preclinical research: bioivt.com/resources/arti…

Interesting symposium with great presentations:

Do you know which #invitro #drugmetabolism and drug-#druginteraction studies you actually need to perform? While there may not be an exact checklist, regulatory agencies have made some expectations clear... bioivt.com/blogs/what-in-…

After Dr. Limaye presented #ADME and drug- #druginteraction studies geared towards a #toxicology audience, we posted the important highlights from the presentation in our blog here: bioivt.com/blogs/adme-and… and the slides can be downloaded here: assets.ctfassets.net/wirgejq7s9c7/7…

Next week we’ll send our first news and resources update through BioIVT’s email system and switch to posting through BioIVT’s social media. Make sure you’ve resubscribed (hubs.ly/Q01SQsX-0) and follow BioIVT so you don’t miss out.

Make sure to follow BioIVT to access the poster once it’s available:

Loss of processes inside #hepatocytes, like #drugmetabolism, induction, inhibition (metabolic and #drugtransporters), #druginteractions and #hepatotoxicity results in subpar #invivo predictions. Learn about model selection in this BioIVT #scientificposter assets.ctfassets.net/wirgejq7s9c7/1…

"When should I be planning my #ADME / #DMPK / drug-#druginteraction studies?" We've got some answers-- read our blog post discussing strategic timing of #invitro #preclinical studies to set your drug compound up for success: bioivt.com/blogs/timing-o…

Have questions about our new tiered #invitro #ADME study options? Join Dr. Barbara, BioIVT’s KC Site Lead, for a quick presentation and Q&A on July 27th to learn more about the benefits of each tier and how to decide which is right for you: hubs.ly/Q01XhVW70

Hot off the press!

Drug-induced liver injury (DILI) is the leading cause of acute liver failure. This #scientificposter from BioIVT looks at the effect of drugs that cause cholestatic DILI on bile acid transport and metabolism: assets.ctfassets.net/wirgejq7s9c7/4…

Explore two #transporter case studies highlighting solutions to inconclusive results. AAPS is proud to host the #eChalkTalk, Uncooperative Drugs in In Vitro Transporter Research, on Wednesday, March 27, with BioIVT. This eChalk Talk is free for all: bit.ly/eChalkTalk32524